In several reports (1941a, b, 1942, 1944, 1948) published during recent years Professor Nanna Svartz has -claimed good results in the treatment of rheumatic polyarthritis from the use of a sulphapyridine compound. The drug, which has been given the name salazopyrin, is obtained by the chemical combination of salicylic acid and sulphapyridine and has the formula 4-/pyridyl (2) amido sulphonyl/-3'-Carbody-4'-oxyazobenzene.
It is claimed that the drug has a specific affinity for connective tissue, where subsequent disintegration gives rise to amino-salicylic acid and sulphapyridine. Svartz (1948) believes that the essential lesion in rheumatic disease is located in connective tissue and is inflammatory in nature. On this basis she argues that drugs with an affinity for connective tissue are most likely to be of value in treatment. The value of salicylates in ameliorating the symptoms of rheumatic fever is accepted. Unless organisms are present in the inflamed connective tissue, the desirability of attaining a high local concentration of sulphapyridine is more in doubt. Few observers believe that there is such a disseznination of bacteria in rheumatic fever or in rheumatoid arthritis.
The initial dosage recommended by Svartz was 6 g. in twenty-four hours. This was reduced to 1 to 1-g. daily as the condition improved. In chronic rheumatoid arthritis she advocates the use of the drug over a long period. Some of her patients have consumed 5,000 to 6,000 J-g. tablets in one to two years. Toxic effects are said to be relatively rare, the commonest being fever, skin rashes, nausea, and vomiting. These symptoms subside quickly when the drug is withdrawn.
Svartz divided her cases into acute and chronic rheumatic polyarthritis, and claimed that benefit was obtained in both instances. This classification makes it difficult to assess her results. For the chronic group she also uses the term " chronic rheumatoid arthritis " so the effects of the drug in this group will be considered in more detail. Fletcher (1944) reported on the use of salazopyrin in five cases of rheumatic fever, one of gonococcal arthritis, two of acute infective arthritis, and six of chronic infective arthritis. In this last group only one patient was treated for as long as six months and the total dose was 180 g. This patient and one other, treated for three months, stated that they felt better, but there was little clinical evidence of improvement and the blood sedimentation rate did not return to normal.
The Present Investigation
In view of the substantial claims made by Svartz as to the value of salazopyrin in chronic rheumatoid arthritis it was decided to submit the drug to further clinical trial. A supply of salazopyrin was obtained from Sweden through the courtesy of Professor Svartz, and twenty cases of rheumatoid arthritis were treated. In view of the difficulty in assessing the value of any form of therapy in a chronic disease without adequate coprols, the results in these cases were compared with those obtained in a group receiving gold, and in a third group receiving no specific therapy. All sixty cases were treated initially as in-patients and all were subjected to the same basic regime of treatment in the rheumatic unit. This included rest in bed, dietary supplements, rest iplints, physiotherapy, and remedial exercises. It is recognized that this regime alone will lead to substantial improvement in the majority of cases of rheumatoid arthritis, but it was felt that when the results in the three groups were finally compared in detail, some indication would be obtained as to whether salazopyrin had any specific effect on the disease. The inclusion of a group receiving gold therapy was considered desirable, as it allowed comparison with patients receiving a drug believed to be of real value in this disease.
The clinical details and laboratory investigations in each patient were entered on a chart specially designed for the purpose (see Figure) . The patients were examined 7UMATIC DISEASES and assessed on each o=casion by the same observer (R.J.G.S.). The key to the chart is given in full. 1l was felt that the routine charting of all relevant data at intervals both during in-patient treatment and during the follow-up period by one observer would enable the final assessment of patients in each of the three groups to be made with a reasonable degree of accuracy. The method will be modified and improved in the light of further experience.
The dose of salazopyrin used was initially that recommended by 
SALAZOPYRIN IN RHEUMATOID ARTHRITIS
The theoretical basis for the use of salazopyrin in rheumatoid arthritis-that it has a specific affinity for connective tissue where it disintegrates into sulphapyridin and aminosalicylic acid-cannot be regarded as sound. Salicylates have no specific effect in this disease, nois' has any member of the sulpha group of drugs. Penicillin and streptomycin have been equally ineffective. This is not surprising as few observers now believe that living organisms play a direct part in the production of the changes in connective tissue. Summary 1. The drug salazopyrin has been used in the treatment of twenty cases of rheumatoid arthritis.
2. The results obtained have been compared with those in twenty cases treated with gold and twenty cases in whom no specific therapy was given.
3. All three groups were studied as in-patients and followed up for six to eight months.
4. All three groups underwent the same basic regime of treatment.
5. The method of case-recording is described. 6. Salazopyrin does not appear to be of any specific value in the treatment of this disease.
